GlassScriptPhysician profile
Yuanyuan Long
NPI 1588751523
$6,160.45
in general payments reported to CMS, 2019-2025
27 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $167 · 2021: $649 · 2022: $757 · 2023: $916 · 2024: $2,649 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,519 · Travel and Lodging: $1,003 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,518.71 |
| Travel and Lodging | $1,003.15 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,650.20 | 2021-2025 | |
| Inspire Medical Systems, INC. | $1,439.34 | 2023-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $747.35 | 2020-2025 | |
| Emd Serono, INC. | $371.30 | 2021-2024 | Mavenclad |
| Pfizer INC. | $329.58 | 2023-2025 | |
| Harmony Biosciences LLC | $321.85 | 2023-2025 | Wakix |
| Amgen INC. | $241.32 | 2021-2025 | Uplizna |
| Allergan, INC. | $176.52 | 2020-2022 | |
| Lilly USA, LLC | $122.07 | 2020-2025 | Kisunla, Zepbound |
| Axsome Therapeutics, INC. | $102.18 | 2023-2025 | Sunosi |
| Ucb, INC. | $93.58 | 2020-2025 | Rystiggo, Zilbrysq |
| Idorsia Pharmaceuticals US INC | $81.71 | 2024 | Quviviq |
| Fisher & Paykel Healthcare INC | $59.77 | 2024-2025 | Fisher & Paykel Healthcare |
| Jazz Pharmaceuticals INC. | $53.95 | 2024 | |
| Tg Therapeutics, INC. | $50.91 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $43.27 | 2024-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $38.05 | 2023-2025 | Rytary, Crexont |
| Celgene Corporation | $34.41 | 2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $29.90 | 2024 | Austedo Xr |
| Resmed Corp | $28.06 | 2025 | |
| Neurocrine Biosciences, INC. | $27.61 | 2022-2023 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $22.88 | 2022 | |
| Argenx US, INC. | $21.87 | 2025 | Vyvgart Hytrulo |
| Horizon Therapeutics Plc | $19.76 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.69 | 2025 | Wainua |
| Biohaven Pharmaceutical Holding Company LTD. | $19.15 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuanyuan Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.